NORTH CHICAGO, Ill., Oct. 17, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of…Original Article
FDA Approves Vyalev (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson’s Disease
